Shares of Allakos Inc (NASDAQ:ALLK) have been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.
Analysts have set a one year consensus price target of $96.00 for the company and are expecting that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also given Allakos an industry rank of 58 out of 255 based on the ratings given to related companies.
Several equities analysts have issued reports on the stock. ValuEngine lowered shares of Allakos from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Zacks Investment Research downgraded shares of Allakos from a “buy” rating to a “hold” rating in a research note on Friday, August 16th. Finally, William Blair reiterated a “buy” rating on shares of Allakos in a research note on Friday, August 9th.
Several large investors have recently bought and sold shares of ALLK. Tower Research Capital LLC TRC acquired a new stake in shares of Allakos during the third quarter worth $42,000. Bank of Montreal Can acquired a new stake in shares of Allakos during the second quarter worth $63,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Allakos during the third quarter worth $113,000. Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Allakos during the first quarter worth $142,000. Finally, Metropolitan Life Insurance Co NY lifted its stake in shares of Allakos by 66.5% during the first quarter. Metropolitan Life Insurance Co NY now owns 4,931 shares of the company’s stock worth $199,000 after buying an additional 1,970 shares during the period. Institutional investors and hedge funds own 58.47% of the company’s stock.
Shares of Allakos stock traded down $3.45 on Thursday, hitting $72.72. 258,400 shares of the company traded hands, compared to its average volume of 248,817. The stock’s 50 day moving average price is $73.05 and its 200-day moving average price is $59.64. Allakos has a 52 week low of $30.32 and a 52 week high of $92.84. The company has a market cap of $3.71 billion, a PE ratio of -33.05 and a beta of -1.38.
Allakos (NASDAQ:ALLK) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.04). On average, analysts forecast that Allakos will post -1.88 EPS for the current fiscal year.
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Featured Article: What is Depreciation?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.